Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
First Claim
1. A method of treating or ameliorating an effect of a polycystic disease comprising administering to a patient in need thereof an amount of a modulator of a tumor necrosis factor (TNF) pathway, which is sufficient to treat or ameliorate an effect of a polycystic disease.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to methods of treating or ameliorating an effect of a polycystic disease. More particularly, the methods include administering to a patient in need thereof an amount of a modulator of a tumor necrosis factor (TNF) pathway, which is sufficient to treat or ameliorate an effect of a polycystic disease. Methods of treating or ameliorating an effect of a polycystic kidney disease (PKD) are also provided. Methods are also provided for identifying a candidate compound that may be effective to treat or ameliorate an effect of a polycystic disease or to increase polycystin-2 (PC2) function or decrease Rab11-Family of Interacting Protein2 (FIP2) function. Further provided are methods for identifying a patient having, or who is at risk for developing, a polycystic disease or who would benefit from treatment with a TNF-alpha inhibitor.
35 Citations
25 Claims
- 1. A method of treating or ameliorating an effect of a polycystic disease comprising administering to a patient in need thereof an amount of a modulator of a tumor necrosis factor (TNF) pathway, which is sufficient to treat or ameliorate an effect of a polycystic disease.
- 16. A method of treating or ameliorating an effect of a polycystic kidney disease (PKD) comprising administering to a patient in need thereof an amount of a TNF-alpha inhibitor that is sufficient to treat or ameliorate an effect of PKD.
-
18. A method for identifying a candidate compound that may be effective to treat or ameliorate an effect of a polycystic disease or to increase polycystin-2 (PC2) function or decrease Rab11-Family of Interacting Protein-2 (FIP2) function comprising:
-
(a) contacting a test cell that expresses PC-2 with an amount of a TNF-alpha pathway modulator, which is effective to modulate FIP2 expression in the test cell and/or to disrupt PC2 localization or function at a plasma membrane or a primary cilia of the test cell; (b) further contacting the test cell from step (a) with a candidate compound; and (c) determining whether the candidate compound (1) increases PC2 localization to the plasma membrane of the test cell, to the primary cilia of the test cell, or to both or (2) increases PC2 function or (3) decreases FIP2 expression in the test cell compared to a control cell treated in an identical fashion except that it was not contacted with the candidate compound, wherein a candidate compound that increases PC2 localization to the plasma membrane of the test cell, the primary cilia of the test cell, or both or increases PC2 function or decreases FIP2 expression in the test cell relative to the control cell is indicative that the candidate compound may be effective to treat or ameliorate the effects of a polycystic disease or to increase PC2 function or decrease FIP2 expression. - View Dependent Claims (19, 20, 21, 22, 23, 24)
-
-
25. A method for identifying a patient who may benefit from treatment with a TNF-alpha inhibitor comprising determining whether a patient has an elevated level of TNF-alpha, FIP2, or both, compared to control levels of TNF-alpha, FIP2, or both in a patient population that does not have the polycystic disease, wherein a patient that has an elevated level of TNF-alpha, FIP2, or both compared to the control may benefit from treatment with a TNF-alpha inhibitor.
Specification